Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study) von Leroy, Karen, Audigier Valette, Clarisse, Alexandre, Jérôme, Boussemart, Lise, Chiesa, Jean, Deldycke, Clotilde, Gomez-Rocca, Carlos, Hollebecque, Antoine, Lehmann-Che, Jacqueline, Lemoine, Antoinette, Mansard, Sandrine, Medioni, Jacques, Monnet, Isabelle, Mourah, Samia, Pierret, Thomas, Spaëth, Dominique, Civet, Alexandre, Galoin, Sandrine, Italiano, Antoine

Volltext

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial von Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., Reck, Martin

Volltext

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) von Barlesi, Fabrice, Dr Prof, Mazieres, Julien, Prof, Merlio, Jean-Philippe, Prof, Debieuvre, Didier, MD, Mosser, Jean, Prof, Lena, Hervé, MD, Ouafik, L'Houcine, Prof, Besse, Benjamin, MD, Rouquette, Isabelle, MD, Westeel, Virginie, Prof, Escande, Fabienne, MD, Monnet, Isabelle, MD, Lemoine, Antoinette, Prof, Veillon, Rémi, MD, Blons, Hélène, PharmD, Audigier-Valette, Clarisse, MD, Bringuier, Pierre-Paul, Prof, Lamy, Régine, MD, Beau-Faller, Michèle, MD, Pujol, Jean-Louis, Prof, Sabourin, Jean-Christophe, Prof, Penault-Llorca, Frédérique, Prof, Denis, Marc G, Prof, Lantuejoul, Sylvie, Prof, Morin, Franck, MSc, Tran, Quân, MSc, Missy, Pascale, PhD, Langlais, Alexandra, MSc, Milleron, Bernard, MD, Cadranel, Jacques, Prof, Soria, Jean-Charles, Prof, Zalcman, Gérard, Prof

Volltext

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial von Zalcman, Gérard, Prof, Mazieres, Julien, Prof, Margery, Jacques, MD, Greillier, Laurent, MD, Audigier-Valette, Clarisse, MD, Moro-Sibilot, Denis, Prof, Molinier, Olivier, MD, Corre, Romain, MD, Monnet, Isabelle, MD, Gounant, Valérie, MD, Rivière, Frédéric, MD, Janicot, Henri, MD, Gervais, Radj, MD, Locher, Chrystèle, MD, Milleron, Bernard, MD, Tran, Quan, MSc, Lebitasy, Marie-Paule, MD, Morin, Franck, MSc, Creveuil, Christian, PhD, Parienti, Jean-Jacques, Prof, Scherpereel, Arnaud, Prof

Volltext

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients von Delaunay, Myriam, Cadranel, Jacques, Lusque, Amélie, Meyer, Nicolas, Gounant, Valérie, Moro-Sibilot, Denis, Michot, Jean-Marie, Raimbourg, Judith, Girard, Nicolas, Guisier, Florian, Planchard, David, Metivier, Anne-Cécile, Tomasini, Pascale, Dansin, Eric, Pérol, Maurice, Campana, Marion, Gautschi, Oliver, Früh, Martin, Fumet, Jean-David, Audigier-Valette, Clarisse, Couraud, Sébastien, Dalle, Stéphane, Leccia, Marie-Thérèse, Jaffro, Marion, Collot, Samia, Prévot, Grégoire, Milia, Julie, Mazieres, Julien

Volltext

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma von Domblides, Charlotte, Leroy, Karen, Monnet, Isabelle, Mazières, Julien, Barlesi, Fabrice, Gounant, Valérie, Baldacci, Simon, Mennecier, Bertrand, Toffart, Anne-Claire, Audigier-Valette, Clarisse, Doucet, Ludovic, Giroux-Leprieur, Etienne, Guisier, Florian, Ricordel, Charles, Molinier, Olivier, Perol, Maurice, Pichon, Eric, Robinet, Gilles, Templement-Grangerat, Dorine, Ruppert, Anne-Marie, Rabbe, Nathalie, Antoine, Martine, Wislez, Marie

Volltext

On the relevance of a testing algorithm for the detection of ROS1 -rearranged lung adenocarcinomas von Mescam-Mancini, Lénaïg, Lantuéjoul, Sylvie, Moro-Sibilot, Denis, Rouquette, Isabelle, Souquet, Pierre-Jean, Audigier-Valette, Clarisse, Sabourin, Jean-Christophe, Decroisette, Chantal, Sakhri, Linda, Brambilla, Elisabeth, McLeer-Florin, Anne

Volltext

Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial von Bylicki, Olivier, Guisier, Florian, Scherpereel, Arnaud, Daniel, Catherine, Swalduz, Aurélie, Grolleau, Emmanuel, Bernardi, Marie, Hominal, Stephane, Prevost, Jean.Briac, Pamart, Guillaume, Marques, Marie.Héléne, Cloarec, Nicolas, Deshayes, Simon, Raimbourg, Judith, Veillon, Rémi, Oulkhouir, Youssef, Audigier Valette, Clarisse, Subtil, Fabien, Chouaïd, Christos, Greillier, Laurent

Volltext

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort von Girard, Nicolas, Perol, Maurice, Simon, Gaëtane, Audigier Valette, Clarisse, Gervais, Radj, Debieuvre, Didier, Schott, Roland, Quantin, Xavier, Coudert, Bruno, Lena, Hervé, Carton, Matthieu, Robain, Mathieu, Filleron, Thomas, Chouaid, Christos

Volltext

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 von Ready, Neal E, Audigier-Valette, Clarisse, Goldman, Jonathan W, Felip, Enriqueta, Ciuleanu, Tudor-Eliade, Rosario García Campelo, María, Jao, Kevin, Barlesi, Fabrice, Bordenave, Stéphanie, Rijavec, Erika, Urban, Laszlo, Aucoin, Jean-Sébastien, Zannori, Cristina, Vermaelen, Karim, Arén Frontera, Osvaldo, Curioni Fontecedro, Alessandra, Sánchez-Gastaldo, Amparo, Juan-Vidal, Oscar, Linardou, Helena, Poddubskaya, Elena, Spigel, David R, Ahmed, Samreen, Maio, Michele, Li, Sunney, Chang, Han, Fiore, Joseph, Acevedo, Angelic, Paz-Ares, Luis

Volltext

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial von Maille, Elodie, Brosseau, Solenn, Hanoux, Vincent, Creveuil, Christian, Danel, Claire, Bergot, Emmanuel, Scherpereel, Arnaud, Mazières, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Gounant, Valérie, Langlais, Alexandra, Morin, Franck, Levallet, Guénaëlle, Zalcman, Gérard

Volltext

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice von Tomasini, Pascale, Brosseau, Solenn, Mazières, Julien, Merlio, Jean-Philippe, Beau-Faller, Michèle, Mosser, Jean, Wislez, Marie, Ouafik, L'Houcine, Besse, Benjamin, Rouquette, Isabelle, Debieuvre, Didier, Escande, Fabienne, Westeel, Virginie, Audigier-Valette, Clarisse, Missy, Pascale, Langlais, Alexandra, Morin, Frank, Moro-Sibilot, Denis, Zalcman, Gérard, Barlesi, Fabrice

Volltext

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study von Barlesi, Fabrice, Dixmier, Adrien, Debieuvre, Didier, Raspaud, Christophe, Auliac, Jean-Bernard, Benoit, Nicolas, Bombaron, Pierre, Moro-Sibilot, Denis, Audigier-Valette, Clarisse, Asselain, Bernard, Egenod, Thomas, Rabeau, Audrey, Fayette, Jérôme, Sanchez, Myriam Locatelli, Labourey, Jean-Luc, Westeel, Virginie, Lamoureux, Pauline, Cotte, François-Emery, Allan, Victoria, Daumont, Melinda, Dumanoir, Juliette, Reynaud, Dorothée, Calvet, Christophe Yannick, Ozan, Nicolas, Pérol, Maurice

Volltext

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1 von Ramalingam, Suresh S., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong-Seok, Schenker, Michael, Bernabe Caro, Reyes, Lee, Ki Hyeong, Zurawski, Bogdan, Audigier-Valette, Clarisse, Provencio, Mariano, Linardou, Helena, Kim, Sang-We, Borghaei, Hossein, Hellmann, Matthew David, O'Byrne, Kenneth John, Paz-Ares, Luis G., Reck, Martin, Nathan, Faith Ellen, Brahmer, Julie R.

Volltext

The TAILOR study: To agree or to disagree? von Moro-Sibilot, Denis, Perol, David, Chabaud, Sylvie, Cadranel, Jacques, Audigier Valette, Clarisse, Perol, Maurice

Volltext

“Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.” Myriam Delaunay, Jacques Cadranel, Amélie Lusque, Nicolas Meyer, Valéérie Gounant, Denis Moro-Sibilot, Jean-Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cééécile Metivier, Pascale Tomasini, Eric Dansin, Maurice Péééérol, Marion Campana, Oliver Gautschi, Martin Fruh, Jean-David Fumet, Clarisse Audigier-Valette, Sééééébastien Couraud, Stéééééép

Volltext

"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients." Myriam Delaunay, Jacques Cadranel, Amélie Lusque, Nicolas Meyer, Valérie Gounant, Denis Moro-Sibilot, Jean-Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Metivier, Pascale Tomasini, Eric Dansin, Maurice Pérol, Marion Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, Sébastien Couraud, Stéphane Dalle, Marie-Thérèse Leccia, Ma

Volltext

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial von Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Thiberville, Luc, Urban, Thierry, Ligeza-poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gerard

Volltext

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial von Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Thiberville, Luc, Urban, Thierry, Ligeza-poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gerard

Volltext

782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2nd line anti-PD1/L1 monotherapy in the PIONeeR project von Landri, Marcellin, Vasseur, Margot, Monville, Florence, Leca, Vanina, Hamdad, Chafik, Mercadal, Margaux, Vanhille, Laurent, Kassambara, Alboukadel, Benzekry, Sebastien, Ray, Maryannick Le, Roumieux, Marie, Malkoun, Richard, Boyer, Arnaud, Audigier-valette, Clarisse, Martinez, Stephanie, Pegliasco, Hervé, Ray, Patrice, Falchero, Lionel, Serre, Antoine, Cloarec, Nicolas, Lebas, Louisiane, Hominal, Stéphane, Barré, Patricia, Zahi, Sarah, Frikha, Ahmed, Bory, Pierre, Laborde, Lilian, Mazières, Julien, Pérol, Maurice, Greillier, Laurent, Barlesi, Fabrice, Fieschi, Jacques

Volltext